NO20053561L - Mettede kinoksalinderivater og deres anvendelse som metabotrofe og glutamatreseptorligander - Google Patents

Mettede kinoksalinderivater og deres anvendelse som metabotrofe og glutamatreseptorligander

Info

Publication number
NO20053561L
NO20053561L NO20053561A NO20053561A NO20053561L NO 20053561 L NO20053561 L NO 20053561L NO 20053561 A NO20053561 A NO 20053561A NO 20053561 A NO20053561 A NO 20053561A NO 20053561 L NO20053561 L NO 20053561L
Authority
NO
Norway
Prior art keywords
receptor ligands
glutamate receptor
metabotrophic
saturated
quinoxaline derivatives
Prior art date
Application number
NO20053561A
Other languages
English (en)
Other versions
NO20053561D0 (no
Inventor
Gunnar Nordvall
Helena Gyback
Martin Johansson
Alexander Minidis
Patrick Raboisson
David Wensbro
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20053561D0 publication Critical patent/NO20053561D0/no
Publication of NO20053561L publication Critical patent/NO20053561L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Den foreliggende oppfinnelsen gjelder nye forbindelser med formel (I), hvori Q er en delvis mettet ring eller Ni-oksider, salter, solvater eller solvaterte salter derav, fremgangsmåter for fremstilling av disse og nye mellomprodukter som anvendes for fremstillingen av disse, og anvendelse av nevnte forbindelser som metabotropiske glutamatreseptorligander ved behandling.
NO20053561A 2003-01-31 2005-07-20 Mettede kinoksalinderivater og deres anvendelse som metabotrofe og glutamatreseptorligander NO20053561L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44388903P 2003-01-31 2003-01-31
US53063203P 2003-12-19 2003-12-19
PCT/US2004/002131 WO2004069813A1 (en) 2003-01-31 2004-01-26 Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands

Publications (2)

Publication Number Publication Date
NO20053561D0 NO20053561D0 (no) 2005-07-20
NO20053561L true NO20053561L (no) 2005-10-28

Family

ID=32853344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053561A NO20053561L (no) 2003-01-31 2005-07-20 Mettede kinoksalinderivater og deres anvendelse som metabotrofe og glutamatreseptorligander

Country Status (10)

Country Link
US (1) US20050004130A1 (no)
EP (1) EP1587796A1 (no)
JP (1) JP2006516628A (no)
KR (1) KR20060004907A (no)
AU (1) AU2004209540A1 (no)
BR (1) BRPI0406810A (no)
CA (1) CA2513824A1 (no)
MX (1) MXPA05008186A (no)
NO (1) NO20053561L (no)
WO (1) WO2004069813A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303492D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VII
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041602A (ja) * 1983-08-17 1985-03-05 Sumitomo Chem Co Ltd 土壌病害防除剤
JPS59231068A (ja) * 1983-06-13 1984-12-25 Sumitomo Chem Co Ltd 酸イミド系化合物およびその製造法
US4709052A (en) * 1983-05-31 1987-11-24 Sumitomo Chemical Company, Limited Soil disease-controlling imides
JPS59225101A (ja) * 1983-06-03 1984-12-18 Sumitomo Chem Co Ltd 土壌病害防除剤
JPS59227845A (ja) * 1983-06-09 1984-12-21 Sumitomo Chem Co Ltd 酸アミド系化合物
JPS59222403A (ja) * 1983-05-31 1984-12-14 Sumitomo Chem Co Ltd 土壌病害防除剤
JPS6042303A (ja) * 1983-08-18 1985-03-06 Sumitomo Chem Co Ltd シアノアセトアニリド誘導体を有効成分とする植物病害防除剤
DD220602A1 (de) * 1983-09-13 1985-04-03 Fahlberg List Veb Verfahren zur herstellung von chinoxalin-2-thiocarbonsaeureamiden
JPS60214706A (ja) * 1984-04-05 1985-10-28 Sumitomo Chem Co Ltd 土壌病害防除剤
JPS60224663A (ja) * 1984-04-23 1985-11-09 Sumitomo Chem Co Ltd 酸アミド系化合物
JP2759257B2 (ja) * 1993-09-28 1998-05-28 大塚製薬株式会社 糖尿病治療剤
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU771358B2 (en) * 1997-11-21 2004-03-18 Astrazeneca Ab Metabotropic glutamate receptor antagonists for treating central nervous system diseases
US6429207B1 (en) * 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
NZ515894A (en) * 1999-06-02 2003-09-26 Nps Pharma Inc Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
CN1208321C (zh) * 1999-07-20 2005-06-29 道农业科学公司 杀真菌的杂环芳族酰胺和它们的组合物、使用方法和制备
BR0013469B1 (pt) * 1999-08-20 2011-01-25 amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica.

Also Published As

Publication number Publication date
JP2006516628A (ja) 2006-07-06
BRPI0406810A (pt) 2005-12-27
CA2513824A1 (en) 2004-08-19
WO2004069813A1 (en) 2004-08-19
EP1587796A1 (en) 2005-10-26
AU2004209540A1 (en) 2004-08-19
US20050004130A1 (en) 2005-01-06
MXPA05008186A (es) 2005-10-05
KR20060004907A (ko) 2006-01-16
NO20053561D0 (no) 2005-07-20

Similar Documents

Publication Publication Date Title
NO20053561L (no) Mettede kinoksalinderivater og deres anvendelse som metabotrofe og glutamatreseptorligander
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20055977L (no) Nye benzimidazolderivater
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20066055L (no) Pyridinderivater
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20083684L (no) Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer
NO20082496L (no) Pyrazinderivater
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20070606L (no) Inhibitorer av IAP
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20081217L (no) Nye benzotiazolonderivater
DE60132975D1 (de) Neue substanzen und verbindungen als protease-inhibitoren
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application